CAMBRIDGE, Mass. — March 11, 2019 — Sigilon Therapeutics, a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics™, today announced that Chief Executive Officer Rogerio Vivaldi will present at a number of upcoming high-profile investor and health care conferences.
At the 6th Annual Rare Disease Market Access and Orphan Commercialization Summit, Dr. Vivaldi will share his insights in a panel discussion about how to build a patient-centric internal growth strategy for rare disease therapies. The panel will take place on Monday, March 11, 2019 at 1:45 p.m. EDT at the Hilton Penn’s Landing in Philadelphia, Pennsylvania.
Dr. Vivaldi will present a corporate overview of Sigilon and its groundbreaking new class of medicine, Shielded Living Therapeutics, at the Cowen Group 39th Annual Health Care Conference. The presentation, at the Marriott Copley in Boston, Massachusetts, will take place on March 13, 2019 at 10:30 a.m. EDT.
Finally, Dr. Vivaldi will share updates on Sigilon’s rich pipeline at the 7th Annual Alliance for Regenerative Medicine Cell & Gene Therapy Investor Day. That presentation will take place on Thursday, March 21, 2019 at 4:15 p.m. EDT at the Metropolitan Club in New York City, New York.
About Sigilon Therapeutics
Sigilon Therapeutics is a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics. To create Shielded Living Therapeutics, we engineer novel human cells that we encase in a proprietary immune-shielding matrix and place in the body. These Shielded Living Therapeutics then produce therapeutic proteins in a programmable and durable fashion, without generating fibrosis or immune rejection. Sigilon was founded and created by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Ten Bridge Communications